• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Strategic procurement and international collaboration to improve access to medicines.

作者信息

Ferrario Alessandra, Humbert Tifenn, Kanavos Panos, Pedersen Hanne Bak

机构信息

LSE Health and Social Care, London School of Economics and Political Science, Houghton Street, London WC2A 2AE, England.

Regional Office for Europe, World Health Organization, Copenhagen, Denmark.

出版信息

Bull World Health Organ. 2017 Oct 1;95(10):720-722. doi: 10.2471/BLT.16.187344. Epub 2017 Aug 23.

DOI:10.2471/BLT.16.187344
PMID:29147045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5689188/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c077/5689188/1ba861938e52/BLT.16.187344-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c077/5689188/5754638dc147/BLT.16.187344-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c077/5689188/1ba861938e52/BLT.16.187344-F2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c077/5689188/5754638dc147/BLT.16.187344-F1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c077/5689188/1ba861938e52/BLT.16.187344-F2.jpg

相似文献

1
Strategic procurement and international collaboration to improve access to medicines.通过战略采购和国际合作改善药品可及性。
Bull World Health Organ. 2017 Oct 1;95(10):720-722. doi: 10.2471/BLT.16.187344. Epub 2017 Aug 23.
2
Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology.药品和高质量治疗手段的可及性：临床药理学的全球责任
Med J Aust. 2005 Apr 4;182(7):322-3. doi: 10.5694/j.1326-5377.2005.tb06728.x.
3
Introductory note: The access to Essential Medicines Campaign.引言：基本药物获取运动
Trop Med Int Health. 2001 Nov;6(11):955-6. doi: 10.1046/j.1365-3156.2001.00797.x.
4
The responsibility of research universities to promote access to essential medicines.研究型大学在促进基本药物可及性方面的责任。
Yale J Health Policy Law Ethics. 2003 Summer;3(2):293-300.
5
The role of university technology transfer operations in assuring access to medicines and vaccines in developing countries.大学技术转让业务在确保发展中国家获得药品和疫苗方面的作用。
Yale J Health Policy Law Ethics. 2003 Summer;3(2):301-8.
6
WTO: failure to meet deadline on Doha commitments regarding access to generic drugs.世贸组织：未能在多哈回合关于获取仿制药的承诺方面按时完成任务。
Can HIV AIDS Policy Law Rev. 2003 Apr;8(1):38-40.
7
Threat of compulsory licences could increase access to essential medicines.强制许可的威胁可能会增加基本药物的可及性。
BMJ. 2019 May 28;365:l2098. doi: 10.1136/bmj.l2098.
8
Not just a tragedy: access to medications as a right under international law.不仅仅是一场悲剧：获得药物作为一项国际法规定的权利。
Boston Univ Int Law J. 2003 Fall;21(2):325-71.
9
TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.《与贸易有关的知识产权协定》、药品专利与基本药物的获取：从西雅图到多哈的漫长之路
Chic J Int Law. 2002 Spring;3(1):27-46.
10
A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa.关于2019年冠状病毒病对非洲全民健康覆盖所需基本药物和疫苗的可及性、安全性、质量及可负担性的潜在途径和影响的综述。
Global Health. 2021 Apr 8;17(1):42. doi: 10.1186/s12992-021-00666-8.

引用本文的文献

1
Fostering healthcare system sustainability through efficient practices: Can adopting biosimilars ease the financial burden of rheumatoid arthritis?通过高效实践促进医疗保健系统的可持续性：采用生物类似药能否减轻类风湿性关节炎的经济负担？
F1000Res. 2025 Apr 4;13:1128. doi: 10.12688/f1000research.156983.2. eCollection 2024.
2
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.通往可及治疗之路：依库珠单抗生物类似药用于阵发性夜间血红蛋白尿和非典型溶血尿毒综合征的研发与影响
BioDrugs. 2025 Mar;39(2):281-295. doi: 10.1007/s40259-025-00707-3. Epub 2025 Feb 21.
3

本文引用的文献

1
Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: .欧盟促进仿制药发展的数据独占权例外与强制许可：
J Pharm Policy Pract. 2017 Jun 28;10:19. doi: 10.1186/s40545-017-0107-9. eCollection 2017.
2
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.30个国家丙型肝炎新药的价格、成本及可负担性：一项经济分析
PLoS Med. 2016 May 31;13(5):e1002032. doi: 10.1371/journal.pmed.1002032. eCollection 2016 May.
3
Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe.
Biosimilars in Dermatology Review.
皮肤病学中的生物类似药综述。
J Psoriasis Psoriatic Arthritis. 2024 Jan;9(1):28-35. doi: 10.1177/24755303231212154. Epub 2023 Nov 3.
4
Price negotiation and pricing of anticancer drugs in China: An observational study.中国抗肿瘤药物的价格谈判和定价：一项观察性研究。
PLoS Med. 2024 Jan 2;21(1):e1004332. doi: 10.1371/journal.pmed.1004332. eCollection 2024 Jan.
5
A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.欧洲成员国药品定价与报销合作的态度、感知影响及动机因素的证据综述：欧洲经济区成员国是时候将其在循证决策方面的经验和专业知识应用于当前的药品政策挑战了。
Front Pharmacol. 2021 Nov 12;12:666405. doi: 10.3389/fphar.2021.666405. eCollection 2021.
6
European collaborations on medicine and vaccine procurement.欧洲在医学和疫苗采购方面的合作。
Bull World Health Organ. 2021 Oct 1;99(10):715-721. doi: 10.2471/BLT.21.285761. Epub 2021 Aug 20.
7
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.生物类似药的未来：最大限度地提高免疫介导的炎症性疾病的获益。
Drugs. 2020 Feb;80(2):99-113. doi: 10.1007/s40265-020-01256-5.
8
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.获取新药的障碍：探寻成本上升与预算有限之间的平衡
Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018.
通用名药物与治疗性替代：关于在欧洲实现最佳实践的观点
Br J Clin Pharmacol. 2011 Nov;72(5):727-30. doi: 10.1111/j.1365-2125.2011.03987.x.